The Roles of KRAS in Cancer Metabolism, Tumor Microenvironment and Clinical Therapy

Overview

Journal Mol Cancer

Publisher Biomed Central

Date 2025 Jan 13

PMID 39806421

Authors

Qinglong Ma

Wenyang Zhang

Kongming Wu

Lei Shi

Affiliations

Soon will be listed here.

Abstract

KRAS is one of the most mutated genes, driving alternations in metabolic pathways that include enhanced nutrient uptaking, increased glycolysis, elevated glutaminolysis, and heightened synthesis of fatty acids and nucleotides. However, the beyond mechanisms of KRAS-modulated cancer metabolisms remain incompletely understood. In this review, we aim to summarize current knowledge on KRAS-related metabolic alterations in cancer cells and explore the prevalence and significance of KRAS mutation in shaping the tumor microenvironment and influencing epigenetic modification via various molecular activities. Given that cancer cells rely on these metabolic changes to sustain cell growth and survival, targeting these processes may represent a promising therapeutic strategy for KRAS-driven cancers.

Citing Articles

Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer.

Wu H, Zhang J, Wang Q, Li Z, Li L, Xie Y Sci Rep. 2025; 15(1):6072.

PMID: 39972191 PMC: 11840008. DOI: 10.1038/s41598-025-90963-8.

References

Saliakoura M, Rossi Sebastiano M, Nikdima I, Pozzato C, Konstantinidou G . Restriction of extracellular lipids renders pancreatic cancer dependent on autophagy. J Exp Clin Cancer Res. 2022; 41(1):16. PMC: 8742413. DOI: 10.1186/s13046-021-02231-y. View

Spaan C, de Boer R, Smit W, van der Meer J, van Roest M, Vermeulen J . Grp78 is required for intestinal Kras-dependent glycolysis proliferation and adenomagenesis. Life Sci Alliance. 2023; 6(11). PMC: 10465924. DOI: 10.26508/lsa.202301912. View

Dhanasekaran R, Deutzmann A, Mahauad-Fernandez W, Hansen A, Gouw A, Felsher D . The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2021; 19(1):23-36. PMC: 9083341. DOI: 10.1038/s41571-021-00549-2. View

Mukhopadhyay S, Vander Heiden M, McCormick F . The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. Nat Cancer. 2021; 2(3):271-283. PMC: 8045781. DOI: 10.1038/s43018-021-00184-x. View

Wong C, Xu J, Bian X, Wu J, Kang W, Qian Y . In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. Gastroenterology. 2020; 159(6):2163-2180.e6. DOI: 10.1053/j.gastro.2020.08.016. View

Amendola C, Mahaffey J, Parker S, Ahearn I, Chen W, Zhou M . KRAS4A directly regulates hexokinase 1. Nature. 2019; 576(7787):482-486. PMC: 6923592. DOI: 10.1038/s41586-019-1832-9. View

Bouffet E, Hansford J, Garre M, Hara J, Plant-Fox A, Aerts I . Dabrafenib plus Trametinib in Pediatric Glioma with V600 Mutations. N Engl J Med. 2023; 389(12):1108-1120. DOI: 10.1056/NEJMoa2303815. View

Singhal A, Li B, OReilly E . Targeting KRAS in cancer. Nat Med. 2024; 30(4):969-983. PMC: 11845254. DOI: 10.1038/s41591-024-02903-0. View

Yu W, Lei Q, Yang L, Qin G, Liu S, Wang D . Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J Hematol Oncol. 2021; 14(1):187. PMC: 8572421. DOI: 10.1186/s13045-021-01200-4. View

10.

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

11.

Zhu Q, Zhou H, Wu L, Lai Z, Geng D, Yang W . O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1. Nat Chem Biol. 2022; 18(10):1087-1095. DOI: 10.1038/s41589-022-01085-5. View

12.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

13.

Mughees M, Kaushal J, Sharma G, Wajid S, Batra S, Siddiqui J . Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis. Semin Cancer Biol. 2022; 86(Pt 3):497-512. PMC: 9793433. DOI: 10.1016/j.semcancer.2022.02.017. View

14.

Vettore L, Westbrook R, Tennant D . New aspects of amino acid metabolism in cancer. Br J Cancer. 2019; 122(2):150-156. PMC: 7052246. DOI: 10.1038/s41416-019-0620-5. View

15.

Huang Y, Chen Y, Zhou S, Xie L, Liang K, Xu J . Synthetically Lethal Biomimetic Nutri-hijacker Hitchhikes and Reprograms KRAS Mutation-Driven Metabolic Addictions for Pancreatic Ductal Adenocarcinoma Treatment. ACS Nano. 2023; 17(14):14014-14031. DOI: 10.1021/acsnano.3c04069. View

16.

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View

17.

Liu Y, Deguchi Y, Wei D, Liu F, Moussalli M, Deguchi E . Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nat Commun. 2022; 13(1):2665. PMC: 9106716. DOI: 10.1038/s41467-022-30392-7. View

18.

Koyama S, Akbay E, Li Y, Aref A, Skoulidis F, Herter-Sprie G . STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016; 76(5):999-1008. PMC: 4775354. DOI: 10.1158/0008-5472.CAN-15-1439. View

19.

de Langen A, Johnson M, Mazieres J, Dingemans A, Mountzios G, Pless M . Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS mutation: a randomised, open-label, phase 3 trial. Lancet. 2023; 401(10378):733-746. DOI: 10.1016/S0140-6736(23)00221-0. View

20.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View